Abbott has secured CE-mark approval for its new longer-length Esprit BTK system (76mm) for the treatment of chronic limb-threatening ischaemia (CLTI). The approval follows US Food and Drug Administration (FDA) clearance of the longer-length system earlier this year.
Abbott notes in a press release that the longer-length Esprit addresses a real-world clinical need: most below-the-knee (BTK) lesions in CLTI patients exceed 100mm, while existing lengths can require multiple scaffolds, increasing procedural time and complexity. The 76mm length allows physicians to treat longer lesions with fewer devices. It builds on Abbott’s proven Esprit BTK platform and over-the-wire (OTW) design, which is noted to be the only dissolving resorbable scaffold (DRS) on the market with robust long-term clinical evidence.
Samih Al Mawass, divisional vice president for Europe, the Middle East, and Africa (EMEA), Abbott Vascular, commennted: “Abbott has long been at the forefront of dissolving scaffold innovation, and we continue to build on that legacy to address unmet needs in vascular care. The longer-length Esprit scaffold was developed with the realities of clinical practice in mind, where below-the-knee lesions in patients with chronic limb-threatening ischaemia are often extensive and difficult to treat. This CE mark represents an important advancement for physicians across Europe, providing a dedicated solution for complex cases while expanding treatment options for patients at risk of limb loss.”
